Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Proteome Sciences ( (GB:PRM) ) has shared an announcement.
Proteome Sciences reported its final results for 2024, highlighting a total revenue of £4.89 million, a slight decrease from the previous year. Despite a challenging start due to the global downturn in biotech and pharma markets, the company saw a strong recovery in the second half of 2024, driven by increased customer orders and the launch of new products like TMTpro 35 plex tags. The company secured significant contracts, including a GCLP contract with a US biopharmaceutical company, and expanded its service offerings with data-independent acquisition and single-cell proteomics. Looking forward, Proteome Sciences anticipates substantial growth, with a robust order pipeline extending into 2026, supported by investments in new laboratory facilities and equipment.
More about Proteome Sciences
Proteome Sciences plc is a specialist provider of contract proteomics services aimed at drug discovery, development, and biomarker identification. The company utilizes proprietary workflows for analyzing tissues, cells, and body fluids, offering products like SysQuant® and TMT®MS2 for identifying biological targets and mechanisms, as well as Super-Depletion and TMTcalibrator™ for biomarker discovery. Their services are targeted towards the biopharma industry, with a significant market focus in the United States.
YTD Price Performance: 12.94%
Average Trading Volume: 207,412
Technical Sentiment Signal: Strong Buy
Current Market Cap: £11.31M
For an in-depth examination of PRM stock, go to TipRanks’ Stock Analysis page.